17 citations
,
January 2019 in “Journal of cancer” The formula YH0618 can reduce the harmful side effects of the chemotherapy drug Doxorubicin and protect healthy cells.
2 citations
,
December 1997 in “Journal of The American Academy of Dermatology” The document concludes that doctors should monitor children's brain development when treating hemangiomas with interferon alfa and consider stopping the treatment if problems arise, while also exploring drugs that might counteract side effects.
January 1954 in “DMW - Deutsche Medizinische Wochenschrift”
11 citations
,
November 2020 in “bioRxiv (Cold Spring Harbor Laboratory)” Early treatment with azithromycin and other drugs reduced COVID-19 symptoms and complications.
June 2021 in “Research Square (Research Square)” Sudanese epilepsy patients often experience hair loss from anti-epileptic drugs but continue their medication regardless of cosmetic side effects.
June 2026 in “Eurasian Journal of Medicine”
10 citations
,
October 2010 in “Hepatology” Certain liver diseases respond well to specific treatments and have varying risks for liver cancer.
4 citations
,
January 2019 in “PubMed” Low dose valproate in epileptic children mainly causes weight gain and other non-life-threatening side effects.
37 citations
,
January 1979 in “Archives of Dermatology” PUVA treatment may have triggered lupus in a woman with psoriasis.
May 2021 in “Letters in Applied NanoBioScience” Pranlukast and mirabegron may work as new diabetes drugs.
19 citations
,
May 2009 in “Pediatric Dermatology” A 5-year-old girl's scalp scarring and hair loss from lupus improved with specific medications.
Lupus severely affects daily life, work, and mental health, with many experiencing frequent flares and medication side-effects.
13 citations
,
July 2019 in “Toxicology research” Ethanamizuril is safe for rats at 20 mg/kg feed, but higher doses cause hair loss, organ changes, and liver, kidney, and lung damage.
3 citations
,
January 2012 in “Shijie zhongxiyi jiehe zazhi” The compound zishenqing formula is effective and safe for treating mild to moderate systemic lupus erythematosus.
4 citations
,
July 1996 in “Annals of Internal Medicine” High doses of fluconazole can cause reversible hair loss.
52 citations
,
January 2022 in “Current Research in Pharmacology and Drug Discovery” New treatments for COVID-19 show promise, but more effective antiviral drugs are needed.
17 citations
,
January 2021 in “Dermatology and Therapy” Laser-assisted drug delivery has shown improved treatment outcomes for skin conditions and has potential to reduce side effects and treatment time.
September 2023 in “JAAD case reports” A man developed oral hairy leukoplakia while on baricitinib, a medication for alopecia and arthritis, and doctors should watch for such side effects.
6 citations
,
November 1999 in “Psychiatric services” A woman lost all her hair after overdosing on divalproex, but it grew back while still on the medication.
2 citations
,
June 2020 in “AIDS” Recreational drug use can cause misdiagnosed conditions and drug interactions in HIV patients.
March 2020 in “Poster presentations” Accurate diagnosis of SLE requires extensive testing due to its complex symptoms.
13 citations
,
January 2021 in “The American journal of gastroenterology” Sirolimus effectively reduces lesions and improves quality of life in Blue Rubber Bleb Nevus Syndrome with manageable side effects.
2 citations
,
September 2021 in “Curēus” Tofacitinib may be safe for COVID-19 patients with alopecia without worsening symptoms, based on two cases.
87 citations
,
July 2012 in “Expert Review of Clinical Immunology” Pregnancy can increase lupus activity, but careful planning and treatment can improve outcomes.
February 2026 in “Oncology Reviews” Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.
January 2022 in “Medical research archives” Taking vitamin D might improve life for MS patients and reduce skin side effects from alemtuzumab treatment.
Low-level laser therapy may help uninfected cells but has different effects on coronavirus-infected cells.
June 2025 in “British Journal of Dermatology” Ruxolitinib helped a woman with a genetic mutation regrow her hair and improved her health.
September 2019 in “Philippine Journal of Internal Medicine” Early immunosuppressive therapy leads to favorable outcomes in Filipino lupus patients with myocarditis.
December 2025 in “Dermatology Reports” Topical ruxolitinib quickly improves non-segmental vitiligo.